Regeneron Anticipates No Impact from New US Pharma Tariffs

• The Trump administration plans to announce new tariffs as soon as Thursday against drugmakers without price reduction agreements
• Regeneron is the sole holdout among 17 large pharmaceutical companies that received letters from President Trump in July requesting price commitments
• Other drugmakers have already committed to 'most-favoured-nation' pricing, selling drugs through a new government platform, and pledged billions in U.S. investments

Summary

Key Development:

Regeneron Pharmaceuticals announced Thursday it expects to be excluded from new U.S. pharmaceutical tariffs targeting drugmakers that haven't agreed to lower U.S. drug prices. The company anticipates finalizing a deal with the Trump administration "in the near future."

Critical Context:

The Trump administration is set to announce new tariffs as soon as Thursday against pharmaceutical companies that have not reached price reduction agreements. Regeneron is the only company among 17 large drugmakers that received letters from President Trump in July 2020 that has yet to sign such an agreement.

Deal Terms:

Regeneron's forthcoming agreement will include:

• Reduced prescription drug prices for the government's Medicaid program
• Lower costs for cash-paying patients
• Alignment with commitments made by other drugmakers

Industry-Wide Commitments:

Other pharmaceutical companies have already agreed to:

• "Most-favored-nation" pricing structures
• Direct drug sales to consumers through a new government platform
• Billions of dollars in U.S. investments

Market Implications:

The tariff threat represents the administration's enforcement mechanism to pressure drugmakers into price concessions. Regeneron's proactive announcement suggests the company aims to avoid potential trade penalties that could impact its cost structure and market positioning. The pharmaceutical sector faces increasing government pressure to reduce drug prices, with tariffs emerging as a novel policy tool to achieve compliance. Companies that fail to reach agreements face potential financial penalties through tariffs, creating strong incentives for negotiation.